Humana (NYSE:HUM) Price Target Raised to $587.00

Humana (NYSE:HUM) had its target price lifted by Barclays from $582.00 to $587.00 in a research note released on Monday morning,Benzinga reports. They currently have an overweight rating on the insurance provider’s stock.

HUM has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 14th. Evercore upgraded shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price objective for the company in a research note on Wednesday, July 29th. Bank of America upgraded shares of Humana from a “neutral” rating to a “buy” rating and set a $500.00 price objective for the company in a research note on Wednesday, July 29th. Morgan Stanley raised shares of Humana from an “underweight” rating to an “overweight” rating in a report on Friday, October 9th. Finally, JPMorgan Chase & Co. upped their target price on shares of Humana from $316.00 to $393.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. Twenty-one investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $472.17.

Humana Stock Up 1.9%

Shares of NYSE:HUM opened at $446.33 on Monday. The stock has a fifty day simple moving average of $406.79 and a two-hundred day simple moving average of $314.80. The stock has a market capitalization of $53.60 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 2.30 and a beta of 0.65. Humana has a 12-month low of $163.11 and a 12-month high of $456.50. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61.

Humana (NYSE:HUM) last released its earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm had revenue of $41.16 billion for the quarter, compared to analysts’ expectations of $40.87 billion. During the same period in the prior year, the firm posted $3.24 earnings per share. The company’s quarterly revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. On average, research analysts anticipate that Humana will post 9.56 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be given a dividend of $0.8850 per share. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. Humana’s dividend payout ratio (DPR) is 34.44%.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently bought and sold shares of HUM. Vista Investment Partners LLC bought a new position in Humana in the third quarter valued at about $3,254,000. Manning & Napier Advisors LLC bought a new stake in shares of Humana during the 2nd quarter valued at about $1,412,000. The Manufacturers Life Insurance Company grew its stake in shares of Humana by 10.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider’s stock valued at $27,879,000 after purchasing an additional 6,690 shares during the period. Pzena Investment Management LLC bought a new stake in shares of Humana during the 2nd quarter valued at about $1,749,014,000. Finally, Ameritas Advisory Services LLC purchased a new stake in shares of Humana during the 2nd quarter valued at about $1,709,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Headlines Impacting Humana

Here are a few of the latest headlines about HUM:

• Positive Sentiment: Humana’s stronger earnings outlook has bolstered optimism: the company raised its 2026 adjusted EPS floor to $9.50 from $9.00 after reporting favorable insurance-benefit metrics. A Zacks upgrade to Rank #1 (Strong Buy) adds to the positive earnings sentiment. Article: Humana Upgraded to Strong Buy
• Positive Sentiment: Several analysts have lifted price targets following the earnings update. JPMorgan raised its target to $484, while TD Cowen increased its target to $430, reflecting improved expectations even as the firms retained neutral or hold ratings. Article: JPMorgan raises Humana price target
• Neutral Sentiment: Humana also launched cash tender offers for up to $1.5 billion of senior notes. The move signals active debt management, though its effect on the stock may depend on the terms and impact on the company’s balance sheet. Article: Humana shares gain as investors digest outlook and debt tender

Humana Company Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.